NCT04965701View on ClinicalTrials.gov

First Line Osimertinib in the Real World: an Inter-regional Prospective Study

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

June 1, 2022

Study Completion Date

May 31, 2023

Conditions
EGF-R Positive Non-Small Cell Lung Cancer
Interventions
DRUG

Osimertinib 80 MG

Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.

Trial Locations (1)

35128

Istituto Oncologico Veneto, Padua

All Listed Sponsors
lead

Istituto Oncologico Veneto IRCCS

OTHER

NCT04965701 - First Line Osimertinib in the Real World: an Inter-regional Prospective Study | Biotech Hunter | Biotech Hunter